Abstract
Objectives To evaluate the efficacy of safflower yellow in the acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods In a prospective, randomized, controlled trial, 127 patients who met the inclusion criteria were enrolled and were randomly divided into two groups. The control group included 64 patients treated according to the global strategy for diagnosis, management, and prevention of COPD (www.goldcopd.org, updated 2011). The intervention group included 63 patients who received intravenous infusions of safflower yellow (100 mg of safflower yellow dissolved in 250 ml 0.9% saline) once daily for 14 consecutive days in addition to standard diagnosis and treatment. The difference in the average length of the hospital stay between the two groups of patients was determined. The follow-up period was 28 days; the differences in symptoms, clinical indicators, and 28-day mortality in the two groups were compared. Statistical analysis was conducted using SPSS 22.0 software to determine whether there were statistically significant differences (P <0.05) between groups. Results There were no statistically significant differences between the intervention group and the control group in changes in secondary indicators. There were no statistically significant differences in the 28-day mortality or in the survival curves of the two groups (P=0.496 and P=0.075, respectively). Safflower yellow treatment of AECOPD may relieve the patient's clinical symptoms, such as dyspnoea, shorten the average length of hospital stay (P=0.006, respectively), and decrease the duration of mechanical ventilation. Conclusion Safflower yellow in the treatment of AECOPD has a degree of clinical value. This trial is registered under the identifier ChiCTR-IPR-17014176.
Highlights
Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity and mortality due to chronic disease
From March 1, 2013, to March 31, 2015, we collected and observed patients with acute exacerbation of chronic obstructive pulmonary disease (COPD) (AECOPD) who were admitted to the Department of Respiratory Medicine of the People’s Hospital of Pujiang County
During the 25-month study period, a total of 143 patients with AECOPD were admitted to our hospital
Summary
Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity and mortality due to chronic disease. Based on studies conducted at global obstructive pulmonary disease institutions, it is estimated that, by 2020, COPD will be the third leading cause of death in the world and the fifth largest source of global economic burden due to disease [1]. As a result of global common concern, a “Global Strategy for the Diagnosis, Management, and Prevention of COPD” was produced by the Global Initiative for Chronic Obstructive Lung Disease (GOLD); this document was published as a 2007 edition [3], a 2011 edition [4], and a 2017 update [2]. The management of acute exacerbation of COPD (AECOPD) includes both nondrug treatment and drug treatment. The effect of currently available treatment regimens can only move patients from the acute exacerbation stage into a stable stage and cannot achieve the purpose of complete cure
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Evidence-Based Complementary and Alternative Medicine
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
